Trust Co. of Toledo NA OH Has $282,000 Stock Holdings in Baxter International Inc. $BAX

Trust Co. of Toledo NA OH decreased its holdings in shares of Baxter International Inc. (NYSE:BAX) by 10.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 9,301 shares of the medical instruments supplier’s stock after selling 1,119 shares during the period. Trust Co. of Toledo NA OH’s holdings in Baxter International were worth $282,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Dodge & Cox increased its stake in shares of Baxter International by 2.1% during the 1st quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock worth $1,761,439,000 after purchasing an additional 1,081,631 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Baxter International by 1.1% during the 1st quarter. Ameriprise Financial Inc. now owns 7,540,942 shares of the medical instruments supplier’s stock worth $258,140,000 after purchasing an additional 83,973 shares during the last quarter. Sound Shore Management Inc. CT increased its stake in shares of Baxter International by 13.7% during the 1st quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier’s stock worth $96,731,000 after purchasing an additional 341,321 shares during the last quarter. Amundi increased its stake in shares of Baxter International by 9.5% during the 1st quarter. Amundi now owns 1,444,705 shares of the medical instruments supplier’s stock worth $45,292,000 after purchasing an additional 125,431 shares during the last quarter. Finally, ARGA Investment Management LP increased its stake in shares of Baxter International by 52.5% during the 1st quarter. ARGA Investment Management LP now owns 1,327,946 shares of the medical instruments supplier’s stock worth $45,456,000 after purchasing an additional 457,345 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Analyst Upgrades and Downgrades

BAX has been the topic of several analyst reports. Citigroup dropped their price target on shares of Baxter International from $34.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 9th. Stifel Nicolaus reiterated a “hold” rating and issued a $25.00 target price (down from $36.00) on shares of Baxter International in a research note on Monday, August 4th. Evercore ISI lowered their target price on shares of Baxter International from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Wells Fargo & Company lowered their target price on shares of Baxter International from $33.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Finally, Barclays lowered their target price on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a research note on Monday, August 4th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.89.

Baxter International Price Performance

Shares of Baxter International stock opened at $21.95 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49. Baxter International Inc. has a fifty-two week low of $21.33 and a fifty-two week high of $37.74. The firm has a fifty day moving average price of $23.57 and a two-hundred day moving average price of $27.73. The company has a market cap of $11.27 billion, a PE ratio of -73.15, a price-to-earnings-growth ratio of 0.72 and a beta of 0.58.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The company had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.82 billion. During the same period last year, the company earned $0.68 earnings per share. Baxter International’s revenue for the quarter was up 4.3% on a year-over-year basis. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Analysts expect that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th were issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, August 29th. Baxter International’s dividend payout ratio (DPR) is presently -226.67%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.